Markets Stifel starts coverage on 10 rare disease-focused companies Stifel began coverage on 10 rare disease-focused companies, with seven “buy” and three “hold” ratings, noting that with an estimated 7,000-plus rare diseases – 95% of which lack approved therapy – these are early... March 1, 2021